Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride modifies 5-alpha-reductases through a two-step process, affecting inhibitor potency and possibly causing side effects.

This study found that dermatological adverse events from interferon-alpha/ribavirin treatment for chronic hepatitis C are associated with factors like older age, pre-existing skin conditions, cirrhosis, and the use of pegylated interferon formulations.

This study reported that 5 alpha-reductase type 2 is the predominant enzyme in pubic skin fibroblasts across normal men, women, and hirsute patients, suggesting potential treatment options for idiopathic hirsutism.

This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.

This review discusses sexual side effects in men with androgenic alopecia treated with 5-alpha reductase inhibitors and reports no new clinical findings.

This case report describes a 29-year-old woman with longstanding alopecia areata who experienced improvement in her scalp hair loss after 7 years of topical treatment with squaric acid dibutylester.

This study found that variations in sleep patterns, free testosterone, and 5-alpha-reductase type 1 activity are associated with changes in sebum excretion in women, which may contribute to variability in acne studies.

This study suggests that 5-alpha reductase inhibitors may reduce invasive cancer features and improve survival in men undergoing radical cystectomy for high-grade urothelial carcinoma, although further research is needed to confirm these findings.

This article examines 5 alpha-reductase inhibitors and their link to persistent sexual dysfunction, but it reports no new clinical findings.

This review discusses the potential of plant-derived phytochemicals as alternatives to 5-alpha-Reductase inhibitors in treating prostate cancer, highlighting possible benefits like reduced side effects, but it reports no new findings.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

Finasteride, a drug that changes testosterone to a different hormone, was studied and its effects over time were modeled successfully.

Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.

This study found that for men with moderate-to-severe LUTS/BPH, 6 months of treatment with tamsulosin plus the hexanic extract of S. repens was as effective as tamsulosin plus a 5-alpha-reductase inhibitor but had better tolerability.

This review discusses sexual dysfunction as a potential side effect of drugs for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms and reports no new clinical results; it emphasizes the need for methodologically robust studies.

The source does not provide an abstract for this letter to the editor, so specific results regarding the long-term efficacy and safety of dutasteride for male androgenetic alopecia are not reported.

This study found no increased frequency of the TNF2 allele in Mexican patients with adverse cutaneous drug reactions mediated by delayed hypersensitivity, suggesting its lower relevance compared to findings in Caucasian populations.

Finasteride reduces prostate size and symptoms with few side effects.

This study suggests that TGF-alpha may function in an autocrine or juxtacrine manner rather than promoting cell proliferation during hair growth cycles in ferrets and sheep.

This study used single-cell techniques and lineage tracing to reveal that integrin α6 expression in neural crest cells can differentiate them into Schwann cells, melanocytes, and fibroblasts in skin, identifying integrin α6 as a potential marker for these derivatives.

In this study, the authors reported that dutasteride significantly reduced total remission time for COVID-19 symptoms in men compared to placebo, especially for fatigue and loss of taste or smell.

This letter reports no new findings and discusses potential concerns regarding 5-alpha reductase inhibitors on lung function, suggesting a reason for discontinuation during the COVID-19 pandemic.

This study found that oral pulse steroids significantly reduced serum and tissue levels of TNF-α in patients with alopecia areata, correlating with clinical improvement.

Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.

This review examines the use of 5-alpha-reductase inhibitors for treating benign prostatic hyperplasia, noting moderate positive effects without complete cure and the need for further research to understand drug mechanisms and pathogenesis.

This review summarizes the association between 5-alpha reductase inhibitors and depression, discussing potential mechanisms such as neuroactive steroid alterations and neuroinflammation, but reports no new clinical results.

This study found that patients with non-muscle invasive bladder cancer who were treated with 5-alpha reductase inhibitors had lower recurrence rates and higher recurrence-free survival rates compared to untreated patients.

This study found no significant increase in depression risk associated with taking five-alpha reductase inhibitors for benign prostatic hyperplasia or alopecia, although further studies are needed to confirm these findings.

This study found no positive association between the use of 5α-reductase inhibitors and the risk of male breast cancer.

This abstract reports funding sources for ongoing research and does not present any study results.